Version 1
: Received: 23 May 2024 / Approved: 24 May 2024 / Online: 24 May 2024 (08:36:57 CEST)
How to cite:
Jager, A.; Oddens, J. R.; Postema, A. W.; Miclea, R. L.; Schoots, I.; Nooijen, P.; van der Linden, H.; Barentsz, J.; Heijmink, S.; Wijkstra, H.; Mischi, M.; Turco, S. Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?. Preprints2024, 2024051616. https://doi.org/10.20944/preprints202405.1616.v1
Jager, A.; Oddens, J. R.; Postema, A. W.; Miclea, R. L.; Schoots, I.; Nooijen, P.; van der Linden, H.; Barentsz, J.; Heijmink, S.; Wijkstra, H.; Mischi, M.; Turco, S. Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?. Preprints 2024, 2024051616. https://doi.org/10.20944/preprints202405.1616.v1
Jager, A.; Oddens, J. R.; Postema, A. W.; Miclea, R. L.; Schoots, I.; Nooijen, P.; van der Linden, H.; Barentsz, J.; Heijmink, S.; Wijkstra, H.; Mischi, M.; Turco, S. Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?. Preprints2024, 2024051616. https://doi.org/10.20944/preprints202405.1616.v1
APA Style
Jager, A., Oddens, J. R., Postema, A. W., Miclea, R. L., Schoots, I., Nooijen, P., van der Linden, H., Barentsz, J., Heijmink, S., Wijkstra, H., Mischi, M., & Turco, S. (2024). Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?. Preprints. https://doi.org/10.20944/preprints202405.1616.v1
Chicago/Turabian Style
Jager, A., Massimo Mischi and Simona Turco. 2024 "Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?" Preprints. https://doi.org/10.20944/preprints202405.1616.v1
Abstract
In this multicenter, retrospective study we evaluated the added value of magnetic resonance dispersion imaging (MRDI) to standard multiparametric MRI (mpMRI) for PCa detection. The study included 76 patients - 51 with clinically significant prostate cancer (csPCa), who underwent radical prostatectomy and had an mpMRI including dynamic contrast enhanced-MRI. Two radiologists performed three separate randomized scorings based on mpMRI, MRDI and mpMRI+MRDI. Radical prostatectomy histopathology was used as the reference standard. Imaging and histopathology were both scored according to the Prostate Imaging-Reporting and Data System V2.0 sector map. Sensitivity and specificity for PCa detection were evaluated for mpMRI, MRDI and mpMRI+MRDI. Inter- and intra-observer variability for both radiologists were evaluated using Cohen’s Kappa. On a per patient level, sensitivity for csPCa for radiologist 1 (R1) for mpMRI, MRDI and mpMRI+MRDI were 0.94, 0.82 and 0.94, respectively. For the second radiologist (R2) these were 0.78, 0.94 and 0.96. R1 detected 4% additional csPCa cases using MRDI compared to mpMRI and R2 detected 20% extra csPCa cases using MRDI. Inter-observer agreement was significant only for MRDI (Cohen’s kappa = 0.4250, p=0.004). The results of this study show the potential of MRDI to improve interobserver variability and the detection of csPCa.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
